Real-World Study on GLP-1/Basal Insulin Combination for Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by high blood sugar, often requiring basal insulin therapy for management. Despite insulin, many patients struggle with optimal glycemic control and weight management. This study addresses the effectiveness and safety of adding GLP-1 agonist therapy to existing basal insulin regimens in a real-world clinical setting.

The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statistically significant improved glycemic control and weight loss. They also anticipated no higher risk of hypoglycemia compared to baseline. The study involved 150 patients over a 12-month intervention period. > The core hypothesis was that adding GLP-1 agonist therapy to basal insulin would result in statistically significant improvements in glycemic control and weight, without increasing hypoglycemia risk in 150 patients over 12 months. While specific quantitative results (e.g., HbA1c reduction, kg weight loss, p-values) are not provided in this abstract, the study was designed to demonstrate these benefits in a real-world clinical setting. The 150 enrolled patients provided a substantial cohort for evaluating these hypothesized outcomes over the 12-month intervention period, with the goal of showing a positive impact on patient health.